Several reports have demonstrated that inhibiting tumor-associated glutamine metabolism in combination with anti-PD-1/PD-L1 therapies may be a promising approach to restore CD8+ T cell function and overcome resistance. The gene discussed is PDCD1; the disease is neoplasm.